$PTLF,,Not sure how much more this has to go, but
Post# of 23078
(Total Views: 180)
Posted On: 05/26/2017 7:38:57 AM
$PTLF,,Not sure how much more this has to go, but I am riding as far as I can. I got in yesterday @ $.37 (I tried to get this in the .20's) and the price is now $.47. Volume was 6X the average. I will have my eyes on this at the bell to see how investors are reacting.
PETLIFE PHARMACEUTICALS (PTLF) Shorts Decreased By 64.52%
May 25, 2017 - By Marie Mckinney
PETLIFE PHARMACEUTICALS INCORPORATED (OTCMKTS
TLF) had a decrease of 64.52% in short interest. PTLF’s SI was 1,100 shares in May as released by FINRA. Its down 64.52% from 3,100 shares previously. About 196,342 shares traded or 232.64% up from the average. Petlife Pharmaceuticals Inc (OTCMKTSTLF) has 0.00% since May 25, 2016 and is . It has underperformed by 16.70% the S&P500.
PetLife Pharmaceuticals, Inc. is a veterinary pharmaceutical company. The company has market cap of $20.44 million. The Firm specializes in the research, development, sales and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis. It currently has negative earnings. The Firm has developed and is launching veterinary cancer medications and nutraceuticals, based on the Escozine formula.
PETLIFE PHARMACEUTICALS (PTLF) Shorts Decreased By 64.52%
May 25, 2017 - By Marie Mckinney
PETLIFE PHARMACEUTICALS INCORPORATED (OTCMKTS
TLF) had a decrease of 64.52% in short interest. PTLF’s SI was 1,100 shares in May as released by FINRA. Its down 64.52% from 3,100 shares previously. About 196,342 shares traded or 232.64% up from the average. Petlife Pharmaceuticals Inc (OTCMKTSTLF) has 0.00% since May 25, 2016 and is . It has underperformed by 16.70% the S&P500. PetLife Pharmaceuticals, Inc. is a veterinary pharmaceutical company. The company has market cap of $20.44 million. The Firm specializes in the research, development, sales and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis. It currently has negative earnings. The Firm has developed and is launching veterinary cancer medications and nutraceuticals, based on the Escozine formula.
(0)
(0)
'Everything works out in the end,,,If it hasn't worked out,,it's not the end'
https://twitter.com/twitter/statuses/957208055766241280
https://twitter.com/twitter/statuses/957208055766241280